{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008443","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.720498+00:00","generated_at":"2026-06-18T00:52:31.020491+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Graphite Bio enters retention agreements with senior management amid strategic review","bullets":["Retention agreements cover CEO, CFO, and other senior executives, providing lump sum cash equal to 50% of annual base salary upon qualifying termination or Feb 22, 2024.","50% acceleration of unvested equity awards granted in 2023 on qualifying termination after June 30, 2023.","Stock option exercise period extended to 12 months post-termination or original expiry.","Strategic alternatives process is ongoing; retention agreements designed to retain key talent."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008443","json":"https://secwatch.observer/filing/0000950170-23-008443.json","markdown":"https://secwatch.observer/filing/0000950170-23-008443.md","text":"https://secwatch.observer/filing/0000950170-23-008443.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023008443/0000950170-23-008443-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023008443/grph-20230310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:52:31.020491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}